Kytopen’s Post

#Gene and #cell-based therapies have the potential to provide targeted and personalized treatments, according to Charité - Universitätsmedizin Berlin and Bayer. They are a beacon of hope for people for whom conventional therapies have failed or for whom there is no treatment so far. With Charité and Bayer, two partners for major medical progress are coming together who will establish a new center for gene and cell therapy in #Berlin, which is to be established in 2025. More information in first comment #healthforall #teambayer

In May 2024, the 27th Annual Meeting of American Society of Gene & Cell Therapy (ASGCT) explored the current viral vector-based therapy landscape and the emerging vectors in the field. A panel of experts discuss the trends, conversations, and innovations occurring in the viral vector-based therapy sector at ASGCT.   Read what OrganaBio’s Gabrielle Freitas told The Medicine Maker about what techniques and innovations caused most excitement and which players presented promising data and potential solutions for #CGT: https://lnkd.in/eMm9BzGT #celltherapy #genetherapy #immunotherapy #regenerativemedicine

Check out Dr Kara Poons presentation on "Characterization of gene vectors using TEM" on May 10th at the #ASGCT 2024 conference! #TEM #genetherapy #QuTEM #innovation

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

🧬 Are you looking to optimize the manufacturing process of CAR-T therapies from research to commercial production (GMP)? 📍Visit our booth #18 this week in Brussels at the European Society of Gene and Cell Therapy Congress to hear more about how we can support your cell therapy development for CAR-T cells. #viralvector #celltherapy #ESGCT

🎙️🎧 From cell collection to commercial contracting: Advancements in cell & gene therapy manufacturing (Part II) In this episode, Fierce Pharma's Fraiser Kansteiner sits down with Delara Motlagh, head of cell therapy at Catalent Pharma Solutions; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. Together, they discuss cell collection, the critical first step in advanced therapy manufacturing, and the importance of locking in process decisions early and how to effectively scale projects from the lab to the clinic and eventually to the market. Listen below ⬇️🎧 #CellGeneTherapy #CGT #CellandGeneTherapies

Dive into a thought-provoking exploration with imec's Peter Peumans, Natalie Caspari, and Maarten De Groof. They reflect on a roundtable from Advanced Therapies Week 2023, discussing the transformative potential of deep tech in cell and gene therapy development. With breakthroughs like CAR-T cell therapies, the future looks promising. Yet, the journey from a "black-box" approach to a quality-controlled, efficient drug manufacturing process is crucial. Want to delve deeper? Download the full article or explore imec’s White Paper on enhancing cell therapy product manufacturing. 🔗 https://lnkd.in/eFucCW3k #CellAndGeneTherapy #imec #AdvancedTherapiesWeek2023

"It's great to see a willingness to learn and a willingness to take some risk. We should take advantage of this partnership because we're all learning together and delivering value to patients." - Miguel Forte, Kiji Therapeutics The clinical development roadmap for cell and gene therapy is ever-changing. How can we prepare for a more integrated approach to clinical trial design and execution? Brought to you by Precision For Medicine and hosted by Endpoints News. WATCH NOW: https://hubs.ly/Q02xXpMD0 #CGTx #CGTxDay2024 #CellTherapy #GeneTherapy #transformativemedicine

Heading to ASGCT in Baltimore? Come get your groove on at booth #730 or check out our talk to learn how Stunner and Leprechaun can help you bust through bottlenecks in your gene and cell therapy workflows! #ASGCT2024!